rivastigmine   Click here for help

GtoPdb Ligand ID: 6602

Synonyms: Ena 713 free base | Exelon®
Approved drug
rivastigmine is an approved drug (FDA (2000), EMA (1998))
Compound class: Synthetic organic
Comment: Marketed formulations may contain rivastigmine hydrogen tartrate (PubChem CID 14254240).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rivastigmine

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 32.78
Molecular weight 250.17
XLogP 2.29
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCN(C(=O)Oc1cccc(c1)C(N(C)C)C)C
Isomeric SMILES CCN(C(=O)Oc1cccc(c1)[C@@H](N(C)C)C)C
InChI InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
InChI Key XSVMFMHYUFZWBK-NSHDSACASA-N
No information available.
Summary of Clinical Use Click here for help
Used in the treatment of Alzheimer's disease [1].
Rivastigmine-induced cholinesterase inhibition may also be beneficial in vascular cognitive impairment (VCI).
A Phase 2 clinical trial in patients with Parkinson's disease appears to show that rivastigmine (compared to placebo) improves gait dysfunction and decreases the likelihood of falls [2], by ameliorating the underlying cholinergic deficit which contributes to gait and cognitive dysfunction in Parkinson's sufferers. This study is registered with the ISRCTN registry (ID ISRCTN19880883). The study does not address the question of whether the difference between the rivastigmine and placebo groups was due to increased falls in the placebo group as opposed to decreased falls in the rivastigmine group.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The exact mechanism of action of rivastigmine is unknown but it appears to bind reversibly to cholinesterase and butyrylcholinesterase. The resultant enzyme inhibition prevents the hydrolysis of acetylcholine which in turn leads to an increase in acetylcholine at cholinergic synapses.
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)